---
document_datetime: 2026-01-19 11:48:23
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zercepac-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zercepac-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3952568
conversion_datetime: 2026-01-20 20:31:35.746406
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zercepac

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 19/01/2026                          |                                             | SmPC and PL                      | To update Sections 2, 4.4, and 6.1 of the SmPC, |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000320725                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Sections 2, 4.4, and 6.1 of the SmPC, and Sections 2 and 6 of the PL, to include information regarding polysorbates used as excipients in accordance with the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use', following approval of the same change for the reference product. In addition, the MAH took the opportunity to implement minor editorial changes in the Product Information to align with the reference product and the QRD   |            |     | and Sections 2 and 6 of the PL, to include information regarding polysorbates used as excipients in accordance with the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use', following approval of the same change for the reference product.   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000307517 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 21/10/2025 | N/A |                                                                                                                                                                                                                                                                                                                                 |